NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

持續釋放注射

Sustained Release Injectable Drugs

出版商 Greystone Research Associates 商品編碼 996110
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
持續釋放注射 Sustained Release Injectable Drugs
出版日期: 2021年03月18日內容資訊: 英文
簡介

慢性疾病需要長期給藥,而自我給藥更為重要。隨著護理人員交互作用的轉變,藥物安全性和依從性/依從性已成為重要問題。隨著市場上功能強大的新藥數量的增加,這些先前存在的擔憂也越來越多。對於醫療保健專業人員和公共衛生當局,解決這些問題的一種方法是減少給藥頻率。使用旨在調節治療劑作用的製劑技術,藥物開發人員正在開發具有持續釋放特性的製劑。這些化學品包括用於生產新API的封裝和塗層版本的聚合物,例如聚乙二醇複合材料(聚乙二醇化)。目標是解決依賴患者的需求,因此對依從性敏感的藥物治療方案的要求。例如,多次劑量的控釋製劑將導致較不頻繁和期望的治療效果。

本報告分析了全球緩釋(SR)注射藥物市場的結構和趨勢,並分析了目前市場上產品的應用領域和銷售渠道,以及正在試驗和臨床試驗的主要管道產品。我們將為您提供有關進展,主要市場驅動力,市場競爭力(市場份額等)和增長前景(到2028年)以及主要經濟,技術和法規影響的信息。

目錄

執行摘要

  • 注射藥物的市場動態
  • 自我管理趨勢
  • 注射技術
  • 注射裝置設計創新
  • 驅動治療藥物需求的因素
  • 市場因素
  • 競爭形勢
  • 危險因素
  • 品牌SR(持續釋放)注射技術
  • 可生物降解的聚合物
  • 品牌SR配方技術
  • 如何控制物理過程
  • 持續釋放注射劑:發展因素
  • 配方係數
    • 穩定
      • 凍乾
      • 包裝
  • 管理因素
  • SR注入:產品分析和現場預測
  • 成癮
    • 納曲酮
  • 糖尿病
    • 艾塞那□
  • 傳染病
    • 干擾素
  • 激素缺乏
    • 雌二醇
    • 生長激素
    • 睪丸激素
  • 代謝性疾病
    • 肢端肥大症
      • 蘭瑞□
      • 奧曲□
  • 神經症
    • 阿立□唑
    • 氟苯那秦
    • 氟□啶醇
    • 帕潘立酮
    • 奧氮平
    • 利培酮
  • 腫瘤
  • 白血病
    • 長春新鹼
  • 淋巴瘤
    • 阿糖胞甘
  • 前列腺
    • 戈瑟瑞林
    • 碘化鋰
    • 雷公籐甲素
  • 疼痛管理
    • 布比卡因
  • 生殖健康
  • 子宮內膜異位

公司簡介

目錄
Product Code: SRJ2M5K

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with less-frequent dosing.

What You Will Learn:

  • What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
  • What are the major factors driving sustained release injectable drug demand?
  • What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
  • How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
  • What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
  • In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?
  • What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

Table of Contents

Executive Summary

  • Injectable Drug Market Dynamics
  • The Trend toward Self-Administration
  • Injectable Drug Formulation Technology
  • Innovation in Injectable Device Designs
  • Therapeutic Demand Drivers
  • Market Factors
  • Competitive Landscape
  • Risk Factors
  • Sustained Release - Branded Formulation Technologies
  • Biodegradable Polymers
  • Branded SR Formulation Technologies
  • Physical Process Control Methods
  • Sustained Release Injectables - Development Factors
  • Formulation Factors
    • Stability
      • Lyophilization
      • Packaging
  • Administration Factors
  • SR Injectables - Product Analysis & Market Sector Forecasts
  • Addiction
    • Naltrexone
  • Diabetes
    • Exenatide
  • Infectious Disease
    • Interferon
  • Hormone Deficiency
    • Estradiol
    • Somatropin
    • Testosterone
  • Metabolic Diseases
    • Acromegaly
      • Lanreotide
      • Octreotide
  • Neurology
    • Aripiprazole
    • Fluphenazine
    • Haloperidol
    • Paliperidone
    • Olanzapine
    • Risperidone
  • Oncology
  • Leukemia
    • Vincristine
  • Lymphoma
    • Cytarabine
  • Prostate
    • Goserelin
    • Leuprolide
    • Triptorelin
  • Pain Management
    • Bupivacaine
  • Reproductive Health
  • Endometriosis

Company Profiles